1,513
Views
9
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic

, , , , , , , & show all
Pages 799-812 | Received 01 Mar 2017, Accepted 27 Apr 2017, Published online: 07 Jun 2017

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.